Age

18–any

Sex

ALL

Healthy volunteers

Accepted

Patients aged18-years old or over
ECOG score between 0-2
Inoperable stage III or stage IV melanoma
Naïve of treatment or in progression after one or several treatment lines
Give their written consent for the present study and be included in MelBase cohort.
health insurance coverage.
skin or subcutaneous melanoma lesions
agree and inform consent for a cutaneous biopsy or a tumor sample if presenting lymph nodes involvement if part of the usual clinical practice.

Pregnant and breastfeeding women
Patients with psychiatric disorders
Patients already included in another clinical trial
Having received chemotherapy or radiotherapy during the last 4 weeks,
Patient presenting another solid or blood cancer, chronic viral infection (e.g. HIV, HBV or HCV)
Been treated with more than 10mg of steroids until the 4 weeks before inclusion.
Refusal to participate to the study
Patients under guardianship or curatorship
Patients on state medical aid

Study of CD160, an Activating NK Cell Receptor, in Melanoma: a Potential Therapeutic Target?